List of Excipients in Branded Drug RIFADIN IV NOVAPLUS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	RIFADIN IV NOVAPLUS	rifampin	0068-0599	SODIUM FORMALDEHYDE SULFOXYLATE
Sanofi-Aventis US LLC	RIFADIN IV NOVAPLUS	rifampin	0068-0599	SODIUM HYDROXIDE

RIFADIN IV NOVAPLUS Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

RIFADIN IV NOVAPLUS is an intravenous rifampin product used when oral administration is not feasible. Its commercial position depends less on active-ingredient exclusivity than on hospital supply reliability, sterile manufacturing, reconstitution convenience, compatibility, and total cost of administration. The labeled formulation contains rifampin and sodium formaldehyde sulfoxylate in a lyophilized vial. The product is reconstituted with Sterile Water for Injection and further diluted for intravenous infusion.[1]

The strongest commercial opportunities are ready-to-administer presentations, improved stability after reconstitution, reduced manipulation during compounding, lower container and waste costs, and supply continuity. RIFADIN IV is not a biologic and does not face biosimilar competition. Generic competition would proceed through the abbreviated new drug application pathway, subject to applicable reference-product and patent conditions.

What is RIFADIN IV NOVAPLUS?

RIFADIN IV NOVAPLUS is the hospital-distributed intravenous formulation of rifampin, also known as rifampicin. Rifampin is a rifamycin antibacterial used in tuberculosis treatment and in selected serious infections caused by susceptible organisms.[1,2]

The NOVAPLUS designation is generally associated with a private-label or group-purchasing distribution arrangement rather than a separate active ingredient, new chemical entity, or independent clinical formulation. The relevant product attributes are therefore the FDA-approved RIFADIN IV formulation, its labeling, manufacturing source, packaging, and distribution terms.

Product profile

Attribute	RIFADIN IV profile
Active ingredient	Rifampin
Dosage form	Sterile lyophilized powder for injection
Route	Intravenous infusion
Strength	600 mg per vial
Key labeled excipient	Sodium formaldehyde sulfoxylate
Reconstitution	Sterile Water for Injection
Further dilution	Compatible infusion solution specified in labeling
Primary setting	Hospital and other acute-care facilities
Regulatory pathway for competitors	ANDA or, where applicable, 505(b)(2)
Biologic status	Not a biologic; biosimilar pathway does not apply

The formulation is designed around rifampin’s sensitivity to oxidation, its limited aqueous stability, and the need to deliver a high dose by infusion. The reducing excipient helps protect the active ingredient during manufacture and storage. The lyophilized format separates the drug from the aqueous environment until use.

What excipients are used in RIFADIN IV?

The principal formulation excipient identified in the product labeling is sodium formaldehyde sulfoxylate. The vial contains rifampin with this reducing agent in a sterile, freeze-dried presentation.[1]

Why is sodium formaldehyde sulfoxylate used?

Sodium formaldehyde sulfoxylate functions as an oxygen-scavenging or reducing excipient. Its commercial formulation purposes include:

• limiting oxidative degradation of rifampin;
• supporting potency during shelf storage;
• enabling a lyophilized presentation;
• helping preserve solution quality after reconstitution; and
• supporting acceptable color and impurity profiles.

Rifampin is known for intense coloration and formulation sensitivity. The drug can discolor fluids and equipment, and its solutions require controlled handling. The excipient system therefore has both chemical-stability and operational significance.

What formulation constraints affect excipient selection?

An alternative excipient system would need to address several constraints:

1. Oxidative stability. The replacement must control rifampin degradation without creating unacceptable new impurities.
2. Sterile manufacturing compatibility. The excipient must tolerate solution preparation, filtration, filling, and lyophilization.
3. Reconstitution performance. The cake must dissolve rapidly and consistently at the labeled diluent volume.
4. Infusion compatibility. The reconstituted product must remain suitable for dilution and administration through common hospital systems.
5. Toxicological acceptability. New degradation products, residual processing agents, or extractables would require evaluation.
6. Container interaction. Rifampin and its degradants can interact with elastomers, tubing, filters, and infusion bags.
7. Regulatory comparability. A competitor changing the excipient system would need to establish pharmaceutical equivalence or justify a different regulatory pathway.

The most attractive formulation work is therefore not simply replacing one antioxidant with another. It is developing a complete stability and administration package.

What commercial opportunities exist for RIFADIN IV excipient innovation?

The largest opportunities involve hospital workflow rather than therapeutic differentiation.

1. Ready-to-use or ready-to-administer presentations

The existing lyophilized vial requires reconstitution and subsequent dilution. A premixed bag or dual-chamber system could reduce pharmacy labor, preparation errors, and exposure to concentrated rifampin.

Potential formats include:

• a ready-to-use infusion bag;
• a dual-chamber vial-and-diluent system;
• a closed-system transfer device-compatible presentation;
• a pharmacy-prepared bulk container; or
• a smaller-volume concentrated solution for controlled dilution.

A ready-to-use product would require robust in-use stability, container-closure studies, compatibility with infusion devices, and a clear microbial-control strategy. The commercial value would be highest in hospitals with centralized pharmacy compounding and high intravenous antimicrobial utilization.

2. Longer post-reconstitution stability

The label limits the usable period after reconstitution and dilution. A formulation that maintains potency and acceptable particulate and color specifications for longer periods could reduce discarded doses and improve pharmacy scheduling.[1]

A commercial product could target:

• extended room-temperature stability;
• refrigerated storage after preparation;
• compatibility with automated compounding systems; or
• batch preparation for predictable inpatient use.

This opportunity has direct economic value because unused compounded doses create drug waste, labor costs, and inventory inefficiency.

3. Sulfite-reduction or alternative reducing systems

Some institutions prefer to limit excipients associated with hypersensitivity concerns or avoid unnecessary sulfite-type compounds. A new formulation could evaluate alternative reducing systems, such as ascorbate-based, thiol-based, or other pharmaceutically accepted antioxidants.

The opportunity is technically difficult. A replacement excipient must preserve rifampin stability without:

• increasing discoloration;
• changing infusion compatibility;
• introducing new particulate matter;
• altering reconstitution time;
• changing osmolality or pH materially; or
• creating new safety concerns.

A successful sulfite-free or alternative-reducing formulation could support differentiation, but the regulatory benefit would depend on demonstrated clinical and operational value.

4. Container and administration-system optimization

Rifampin’s color and chemical properties create opportunities in packaging and administration materials. Development programs could assess:

• low-binding infusion bags;
• tubing with reduced drug sorption;
• light-protective packaging;
• improved elastomer closures;
• lower-extractables components; and
• integrated in-line filtration or closed transfer.

These changes could be protected through container, device, or combination-product claims even when the active ingredient is unpatented.

5. Reduced-volume presentations

A 600 mg dose requiring large-volume dilution can create storage and administration burdens. A lower-volume presentation could be valuable if it maintains acceptable local tolerance, infusion rate, osmolality, and stability.

The product would need evidence that the revised concentration does not increase:

• phlebitis;
• precipitation risk;
• infusion reactions;
• dosing errors; or
• line incompatibility.

What patents protect RIFADIN IV NOVAPLUS?

RIFADIN IV is based on an old small-molecule antibiotic. The active-ingredient patent estate for rifampin is not expected to provide meaningful current exclusivity. Commercial protection would more likely arise from formulation, manufacturing, packaging, device, or process patents.

Patent categories with potential relevance

Patent category	Commercial relevance
Rifampin compound claims	Low relevance because the compound is long established
Lyophilized formulation claims	Potentially relevant if narrowly drafted and still enforceable
Antioxidant or reducing-excipient claims	Potential protection for a differentiated formulation
Reconstitution and stability claims	Potential protection for extended in-use stability
Ready-to-use infusion claims	Potentially valuable for hospital workflow differentiation
Container or tubing claims	Protection for reduced sorption or improved compatibility
Manufacturing-process claims	Possible protection for sterile lyophilization and impurity control
Method-of-use claims	Limited value where treatment methods are established
Device-combination claims	Relevant to closed transfer and administration systems

A patent search should distinguish the reference product’s approved labeling from independent patents covering improved presentations. The existence of an excipient in a label does not establish that the excipient combination remains patent-protected.

What is the Orange Book status of RIFADIN IV?

RIFADIN IV is an FDA-approved small-molecule drug product, not a biologic. The FDA Orange Book is the relevant source for listed patents, therapeutic-equivalence codes, and reference-product information.[3]

The commercial implications are:

• no biosimilar pathway applies;
• a generic injectable competitor would generally pursue an ANDA;
• Paragraph IV risk depends on any currently listed patents;
• method-of-use listings may affect only specific indications or labeling carve-outs;
• formulation patents may be relevant only if listed and legally enforceable; and
• an absence of meaningful listed patents would shift competition toward manufacturing quality, supply, and price.

Injectable products can face practical barriers even without strong patent protection. These include sterile-facility capacity, analytical method validation, container-closure qualification, impurity control, and FDA inspection readiness.

When does RIFADIN IV lose exclusivity?

Rifampin’s basic small-molecule exclusivity is long expired. The relevant commercial question is not loss of original molecule exclusivity but whether any later formulation, manufacturing, or regulatory exclusivity remains active.

Exclusivity framework

Exclusivity type	Relevance to RIFADIN IV
New chemical entity exclusivity	Expired for rifampin
Orphan-drug exclusivity	Not the primary protection for the marketed product
Pediatric exclusivity	Must be checked against current FDA records
Patent exclusivity	Depends on current Orange Book listings
Injectable formulation protection	May arise from later patents, if any
Regulatory exclusivity for a new formulation	Potentially relevant only for a qualifying new approval
Biosimilar exclusivity	Not applicable

A generic sponsor could challenge any listed patent through a Paragraph IV certification. If no blocking patent remains, the principal risks become ANDA approval timing, manufacturing readiness, and commercial contracting.

Which companies could challenge or compete with RIFADIN IV?

Competition can come from three sources:

1. Generic injectable manufacturers. These companies can develop an equivalent rifampin injection using the reference product as the basis for ANDA development.
2. Hospital-compounding operations. Large health systems and outsourcing facilities may prepare rifampin doses under applicable compounding frameworks, although compounding is not equivalent to an FDA-approved commercial product.
3. Alternative dosage-form suppliers. Oral rifampin, rifampin combinations, and other antimicrobials can reduce demand for intravenous administration when patients can tolerate oral therapy.

Potential competitors must manage rifampin-specific risks, including discoloration, stability, precipitation, aseptic processing, and supply of sterile injectable components. These barriers can reduce the number of viable entrants relative to the number of firms capable of manufacturing oral rifampin.

What generic entry risks exist?

Generic entry would likely exert pressure on price, hospital formulary placement, and contract-manufacturing economics. The risk is highest if a competitor offers a lower-cost vial with equivalent stability and reliable supply.

Generic launch scenarios

Scenario	Market effect
Single generic entrant	Moderate price pressure; reference product may retain supply-based share
Multiple ANDA approvals	Significant price compression and contracting pressure
Ready-to-use generic	Potential displacement of the lyophilized reference product
Shortage-driven entry	Rapid demand shift toward available suppliers
Limited manufacturing capacity	Continued pricing resilience despite weak patent protection
Hospital outsourcing growth	Reduced demand for commercial vials in selected accounts

The highest-value defense is operational differentiation: dependable availability, low preparation burden, stable supply, and packaging that reduces pharmacy labor.

How strong is the RIFADIN IV patent estate?

The patent estate appears structurally weaker than the manufacturing and regulatory barriers. Rifampin itself is a mature molecule, and the commercial product’s defensibility would likely depend on narrow formulation or process claims rather than broad composition-of-matter protection.

Strength assessment

Factor	Assessment
Active ingredient patent strength	Low
Original product exclusivity	Low
Formulation differentiation	Moderate if supported by proprietary stability data
Manufacturing barriers	Moderate to high for sterile injectable production
Device and packaging protection	Potentially moderate
Regulatory complexity	Moderate
Supply-chain defensibility	Potentially high during shortages
Biosimilar protection	None

A new excipient strategy can create a stronger commercial position if it produces measurable performance advantages that are difficult to design around. Claims limited to a conventional antioxidant substitution may be vulnerable to obviousness challenges. Claims tied to a specific impurity profile, stability period, container system, or manufacturing sequence may provide stronger protection when supported by comparative data.

What FDA regulatory pathway applies to a new RIFADIN IV formulation?

A conventional equivalent injectable would generally be developed through an ANDA. A materially different formulation could require a 505(b)(2) application, depending on the extent of the change and the sponsor’s ability to rely on FDA findings for the reference product.[4]

A sponsor developing a new excipient system should expect assessment of:

• pharmaceutical equivalence;
• bioequivalence or equivalent systemic exposure, where applicable;
• sterility and bacterial endotoxin control;
• particulate matter;
• extractables and leachables;
• degradation products;
• container-closure integrity;
• reconstitution time;
• infusion compatibility;
• in-use stability; and
• labeling differences.

A ready-to-use product may create a stronger commercial proposition but also a more demanding development package than a conventional vial copy.

What licensing deals could support the opportunity?

Relevant licensing structures include:

• an excipient technology license for oxidation control;
• a contract development and manufacturing agreement for sterile lyophilization;
• a hospital-distribution agreement through a group purchasing organization;
• a co-development agreement for a ready-to-administer presentation;
• a device license covering closed-system transfer or infusion compatibility; and
• a regional commercialization agreement for tuberculosis-endemic markets.

The most valuable asset for licensing would be comparative data showing lower waste, longer stability, fewer preparation steps, or improved compatibility. A formulation concept without stability, sterility, and container data would have limited transaction value.

What is the geographic commercial opportunity?

Demand is concentrated in hospitals and regions with tuberculosis treatment capacity, severe bacterial infection care, and limited access to oral administration. The opportunity is strongest where injectable supply is inconsistent or pharmacy compounding costs are high.

Potential priority markets include:

• the United States, where hospital purchasing and sterile-product reliability drive value;
• Europe, where centralized procurement can reward low total treatment cost;
• India and other tuberculosis-burden markets, where affordability and supply continuity dominate;
• Latin America, where injectable access varies by public procurement system; and
• markets with high antimicrobial-resistance burdens, where intravenous rifampin may be used in specialist care.

International expansion would require separate assessments of excipient acceptability, local pharmacopoeial standards, serialization, cold-chain requirements, tender rules, and registered manufacturing sites.

Key Takeaways

• RIFADIN IV NOVAPLUS is a lyophilized intravenous rifampin product, not a biologic and not a biosimilar opportunity.
• Sodium formaldehyde sulfoxylate is the key labeled formulation excipient and supports oxidative stability.
• Rifampin’s active-ingredient exclusivity is long expired; commercial defensibility depends on formulation, manufacturing, packaging, supply, and contracting.
• The strongest product opportunities are ready-to-use delivery, longer post-reconstitution stability, lower pharmacy labor, improved container compatibility, and alternative reducing systems.
• A generic equivalent would generally use the ANDA pathway, while a materially differentiated formulation could require a 505(b)(2) strategy.
• Sterile manufacturing, impurity control, container compatibility, and supply reliability are likely greater barriers than molecule-level patent protection.
• The most valuable licensing package would combine excipient technology with comparative stability, waste-reduction, and hospital workflow data.

FAQs

Is RIFADIN IV NOVAPLUS the same drug as rifampin injection?

Yes. RIFADIN IV NOVAPLUS contains rifampin for intravenous infusion. NOVAPLUS generally identifies the distribution or contracting presentation rather than a different active ingredient.

Can sodium formaldehyde sulfoxylate be replaced in an injectable rifampin product?

Potentially, but the replacement must demonstrate equivalent or improved stability, impurity control, reconstitution, sterility, and infusion compatibility. A simple excipient substitution would not automatically qualify as an equivalent product.

Does RIFADIN IV have biosimilar competition?

No. Rifampin is a small-molecule drug. Competing injectable products would generally be regulated as generics or, for materially different formulations, under another drug-approval pathway.

Could a ready-to-use rifampin infusion receive patent protection?

Yes. Protection could potentially cover the formulation, concentration, container, stability period, administration system, or manufacturing process. Patent strength would depend on claim scope, comparative performance, and validity under obviousness and enablement standards.

What is the most attractive commercial improvement for RIFADIN IV?

A ready-to-administer product with extended in-use stability and reduced compounding requirements offers the clearest hospital value proposition. Its commercial success would depend on reliable sterile manufacturing, competitive pricing, and evidence of lower waste and preparation burden.

References

1. U.S. Food and Drug Administration. (n.d.). Rifadin IV: Rifampin for injection prescribing information. Sanofi-Aventis U.S. LLC.

2. Centers for Disease Control and Prevention. (2022). Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases, 63(7), e147-e195.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Guidance and Regulatory Information.